VCNX
Income statement / Annual
Last year (2023), Vaccinex, Inc.'s total revenue was $570,000.00,
an increase of 470.00% from the previous year.
In 2023, Vaccinex, Inc.'s net income was -$20.25 M.
See Vaccinex, Inc.,s key income statements, including revenue, expenses, profit, and income.
Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
Operating Revenue |
$570,000.00 |
$100,000.00 |
$900,000.00 |
$50,000.00 |
$523,000.00 |
$724,000.00 |
$90,000.00 |
$316,000.00 |
Cost of Revenue |
$0.00
|
$207,000.00
|
$169,000.00
|
$2,000.00
|
$199,000.00
|
$1.03 M
|
$160,000.00
|
$115,000.00
|
Gross Profit |
$570,000.00
|
-$107,000.00
|
$731,000.00
|
$48,000.00
|
$324,000.00
|
-$309,000.00
|
-$70,000.00
|
$201,000.00
|
Gross Profit Ratio |
1
|
-1.07
|
0.81
|
0.96
|
0.62
|
-0.43
|
-0.78
|
0.64
|
Research and Development Expenses |
$16.57 M
|
$13.98 M
|
$17.16 M
|
$21.55 M
|
$25.67 M
|
$22.35 M
|
$16.55 M
|
$16.03 M
|
General & Administrative Expenses |
$6.88 M
|
$6.20 M
|
$6.23 M
|
$7.41 M
|
$6.67 M
|
$4.62 M
|
$4.48 M
|
$4.43 M
|
Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
Selling, General & Administrative Expenses |
$6.88 M
|
$6.20 M
|
$6.23 M
|
$7.41 M
|
$6.67 M
|
$4.62 M
|
$4.48 M
|
$4.43 M
|
Other Expenses |
$0.00
|
-$175,000.00
|
$43,000.00
|
-$575,000.00
|
$152,000.00
|
$165,000.00
|
-$40,000.00
|
-$4,000.00
|
Operating Expenses |
$23.46 M
|
$20.01 M
|
$23.39 M
|
$28.38 M
|
$32.34 M
|
$26.97 M
|
$21.03 M
|
$20.46 M
|
Cost And Expenses |
$23.46 M
|
$20.01 M
|
$23.39 M
|
$28.38 M
|
$32.54 M
|
$28.01 M
|
$21.19 M
|
$20.58 M
|
Interest Income |
$0.00
|
$2,000.00
|
$809,000.00
|
$489,000.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
Interest Expense |
$1,000.00
|
$2,000.00
|
$809,000.00
|
$489,000.00
|
$0.00
|
$392,000.00
|
$1.36 M
|
$2.99 M
|
Depreciation & Amortization |
$119,000.00
|
$207,000.00
|
$169,000.00
|
$307,000.00
|
$249,000.00
|
$223,000.00
|
$206,000.00
|
$178,000.00
|
EBITDA |
-$19.75 M |
-$19.61 M |
-$21.40 M |
-$28.06 M |
-$31.61 M |
-$28.90 M |
-$17.20 M |
-$10.78 M |
EBITDA Ratio |
-34.65
|
-196.06
|
-24.75
|
-561.1
|
-60.45
|
-37.15
|
-232.64
|
-63.56
|
Operating Income Ratio |
-40.15
|
-199.06
|
-24.99
|
-566.62
|
-61.21
|
-37.68
|
-234.49
|
-64.11
|
Total Other Income/Expenses Net |
$2.63 M
|
$91,000.00
|
$110,000.00
|
-$520,000.00
|
$152,000.00
|
-$2.24 M
|
$2.35 M
|
$6.32 M
|
Income Before Tax |
-$20.25 M
|
-$19.82 M
|
-$22.38 M
|
-$28.85 M
|
-$31.86 M
|
-$29.52 M
|
-$18.76 M
|
-$13.94 M
|
Income Before Tax Ratio |
-35.53
|
-198.15
|
-24.87
|
-577.02
|
-60.92
|
-40.77
|
-208.43
|
-44.12
|
Income Tax Expense |
$0.00
|
-$93,000.00
|
$852,000.00
|
$458,000.00
|
$152,000.00
|
-$1.85 M
|
$1.28 M
|
$2.99 M
|
Net Income |
-$20.25 M
|
-$19.72 M
|
-$23.23 M
|
-$29.31 M
|
-$32.02 M
|
-$29.52 M
|
-$18.72 M
|
-$13.94 M
|
Net Income Ratio |
-35.53
|
-197.22
|
-25.81
|
-586.18
|
-61.21
|
-40.77
|
-208.02
|
-44.12
|
EPS |
-43.68 |
-97.59 |
-170.04 |
-327.62 |
-521.95 |
-1186.7 |
-689.86 |
-526.85 |
EPS Diluted |
-43.68 |
-97.59 |
-169.11 |
-327.62 |
-521.95 |
-1186.7 |
-689.86 |
-526.85 |
Weighted Average Shares Out |
$463,650.00
|
$202,082.00
|
$136,630.00
|
$89,461.00
|
$61,337.00
|
$24,874.00
|
$27,139.00
|
$26,465.00
|
Weighted Average Shares Out Diluted |
$463,650.00
|
$202,082.00
|
$137,377.00
|
$89,461.00
|
$61,337.00
|
$24,874.00
|
$27,139.00
|
$26,465.00
|
Link |
|
|
|
|
|
|
|
|